Abbisko Cayman (HKSE:02256) Change In Inventory : HK$0.0 Mil (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Change In Inventory?

Abbisko Cayman's change in inventory for the quarter that ended in Jun. 2024 was HK$0.0 Mil. It means Abbisko Cayman's inventory stayed the same from Dec. 2023 to Jun. 2024 .

Abbisko Cayman's change in inventory for the fiscal year that ended in Dec. 2023 was HK$0.0 Mil. It means Abbisko Cayman's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Abbisko Cayman's Total Inventories for the quarter that ended in Jun. 2024 was HK$0.0 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Abbisko Cayman's Inventory-to-Revenue for the quarter that ended in Jun. 2024 was 0.00.

Abbisko Cayman Change In Inventory Historical Data

The historical data trend for Abbisko Cayman's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Change In Inventory Chart

Abbisko Cayman Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Abbisko Cayman Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Change In Inventory	Get a 7-Day Free Trial				-	-	-	-	-

Abbisko Cayman Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

Abbisko Cayman (HKSE:02256) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Abbisko Cayman's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 2
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Abbisko Cayman's Inventory Turnover for the quarter that ended in Jun. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Abbisko Cayman's Inventory to Revenue for the quarter that ended in Jun. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	535.336
	=	0.00

Abbisko Cayman Change In Inventory Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbisko Cayman Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

8ZD:Germany

Address

Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

https://www.abbisko.com

Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.

Executives

Xu Yao-chang	2101 Beneficial owner
Yu Hongping	2501 Other
Chen Zhui	2501 Other
Lav Asset Management (hong Kong) Limited	2102 Investment manager
Shi Yi	2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited	2301 Trustee
Qiming Corporate Gp Vi, Ltd.	2201 Interest of corporation controlled by you
Futu Trustee Limited	2301 Trustee
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Yu Hongping	2501 Other
Morgan Stanley	2201 Interest of corporation controlled by you
Fullerton Management Pte Ltd
Computershare Hong Kong Trustees Limited	2301 Trustee
Morgan Stanley Investments (uk)	2201 Interest of corporation controlled by you
Morgan Stanley International Limited	2201 Interest of corporation controlled by you

Abbisko Cayman Headlines

No Headlines